EUVIMEDEUVIMED entdecken
Crossref

ABO Incompatible Kidney Transplantation in Pakistan: A Major Breakthrough

Naveed Sarwar, Umar Alam, Nubair Sarwar, Nuzhat Mushaid, Sobia Mkhtar, Claudine Lathuile-Giroux, Arshad Mahmood, Lionel Rostaing

Transplantation Proceedings · 2026

DOI: 10.1016/j.transproceed.2025.12.021 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Transplantation Proceedings, 2026. Verfasst von Naveed Sarwar und 7 weiteren Autor:innen. Beteiligte Einrichtung: Bahria international hospital safari, Rawalpindi, Pakistan. Hauptthemen laut MEDLINE: Kidney Transplantation, ABO Blood-Group System, Blood Group Incompatibility, Histocompatibility. Die Arbeit nennt 21 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Pakistan, a resource-limited country, faces a growing number of patients with end-stage kidney disease, many of whom could benefit from living-related kidney transplantation. To expand the living donor pool, we implemented the largest ABO-incompatible kidney transplantation program in the country. The program started in February 2023, and 21 transplants have been performed to date. Pretransplant desensitization consisted of rituximab (375 mg/m²) at day (D) -30, tacrolimus, mycophenolic acid, and steroids starting at D -15, along with apheresis sessions to achieve isoagglutinin titers below 1:4 on the day of transplantation. Among the recipients, 16 were males and 5 females. Eighteen patients had been on hemodialysis for more than 6 months, and 3 underwent pre-emptive transplantation. The median recipient age was 39 years (range, 18-66). After a median follow-up of 12 months (range, 2-32), 3 patients (14.3%) had died with functioning grafts, while no graft loss occurred. The median serum creatinine at last follow-up was 1.1 mg/dL (range, 0.8-1.4). One patient experienced delayed graft function. Three patients developed acute rejection (2 cellular, 1 antibody-mediated), all successfully treated. Infectious complications occurred in ten patients (47.6%), resulting in 2 deaths. In conclusion, ABO-incompatible living donor kidney transplantation is feasible and effective in our setting, achieving excellent short-term graft outcomes. However, infectious and cardiac complications remain significant causes of morbidity and mortality.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Kidney TransplantationABO Blood-Group SystemBlood Group IncompatibilityHistocompatibilityKidney Failure, ChronicHumansFemaleAdultPakistanImmunosuppressive AgentsMiddle AgedMaleAdolescentLiving DonorsAgedYoung AdultTreatment OutcomeGraft SurvivalGraft RejectionDesensitization, ImmunologicTime Factors

Substanzen

ABO Blood-Group SystemImmunosuppressive Agents

Autor:innen und Institutionen

  • Bahria international hospital safari, Rawalpindi, Pakistan.
  • Armed Forces Institute of Urology, Pakistan.
  • PFS blood bank, Rawalpindi, Pakistan.
  • Sarwar kidney care, Rawalpindi, Pakistan.
  • Etablissement français du sang, La Tronche, France.
  • Service de Néphrologie, Hémodialyse, Aphérèses et Transplantation Rénale, Grenoble, France; Université Grenoble Alpes, Grenoble, France. Electronic address: lrostaing@chu-grenoble.fr.

Zitieren

APA

Sarwar, N., Alam, U., Sarwar, N., Mushaid, N., Mkhtar, S., Lathuile-Giroux, C., Mahmood, A., & Rostaing, L. (2026). ABO Incompatible Kidney Transplantation in Pakistan: A Major Breakthrough. Transplantation Proceedings. https://doi.org/10.1016/j.transproceed.2025.12.021

Vancouver

Sarwar N, Alam U, Sarwar N, Mushaid N, Mkhtar S, Lathuile-Giroux C, et al. ABO Incompatible Kidney Transplantation in Pakistan: A Major Breakthrough. Transplantation Proceedings. 2026. doi:10.1016/j.transproceed.2025.12.021

BibTeX
@article{Sarwar2026,
  author = {Sarwar, Naveed and Alam, Umar and Sarwar, Nubair and Mushaid, Nuzhat and Mkhtar, Sobia and Lathuile-Giroux, Claudine and Mahmood, Arshad and Rostaing, Lionel},
  title = {ABO Incompatible Kidney Transplantation in Pakistan: A Major Breakthrough},
  journal = {Transplantation Proceedings},
  year = {2026},
  doi = {10.1016/j.transproceed.2025.12.021}
}
Kostenlos starten →